Advice for Healthcare Professionals The MHRA Drug Safety Update provides the following key guidance for healthcare professionals: Semaglutide treatment may be very rarely associated with NAION, which can cause vision loss, typically in one eye NAION typically presents as sudden, painless vision loss described as blurring or cloudiness Privately prescribed semaglutide may not appear on a patients medical record if a patient presents with these symptoms, enquire about semaglutide use Patients reporting sudden loss of vision (including partial loss) should be urgently referred for specialist examination by an ophthalmologist Discontinue semaglutide treatment if NAION is confirmed Advise new patients, or existing patients during medication reviews, to urgently attend eye casualty or A&E if they experience sudden vision loss or rapidly worsening eyesight An alert advised healthcare professionals to be vigilant for further issues, including rare but serious side effects such as acute pancreatitis
Ready to begin your Functional Medicine journey today
They increase the number of beneficial bacteria, such as and , which produce SCFAs during the fermentation of dietary fibers (see Figure 2)
Refills GLP-1 holds an overall rating of around 4.8 out of 5 based on 2,000+ user reviews , according to on-site claims
These differences underscore that semaglutide is not simply replacement of a deficient hormone but rather pharmacological augmentation of GLP-1 receptor signaling for therapeutic benefit
/assets/images/provider/photos/2776027.png)
